Literature DB >> 16118394

Impact of genetic background on nephropathy in diabetic mice.

Susan B Gurley1, Sharon E Clare, Kamie P Snow, Ann Hu, Timothy W Meyer, Thomas M Coffman.   

Abstract

With the goal of identifying optimal platforms for developing better models of diabetic nephropathy in mice, we compared renal effects of streptozotocin (STZ)-induced diabetes among five common inbred mouse strains (C57BL/6, MRL/Mp, BALB/c, DBA/2, and 129/SvEv). We also evaluated the renal consequences of chemical and genetic diabetes on the same genetic background (C57BL/6). There was a hierarchical response of blood glucose level to the STZ regimen among the strains (DBA/2 > C57BL/6 > MRL/MP > 129/SvEv > BALB/c). In all five strains, males demonstrated much more robust hyperglycemia with STZ than females. STZ-induced diabetes was associated with modest levels of albuminuria in all of the strains but was greatest in the DBA/2 strain, which also had the most marked hyperglycemia. Renal structural changes on light microscopy were limited to the development of mesangial expansion, and, while there were some apparent differences among strains in susceptibility to renal pathological changes, there was a significant positive correlation between blood glucose and the degree of mesangial expansion, suggesting that most of the variability in renal pathological abnormalities was because of differences in hyperglycemia. Although the general character of renal involvement was similar between chemical and genetic diabetes, Akita mice developed more marked hyperglycemia, elevated blood pressures, and less variability in renal structural responses. Thus, among the strains and models tested, the DBA/2 genetic background and the Akita (Ins2(+/C96Y)) model may be the most useful platforms for model development.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16118394     DOI: 10.1152/ajprenal.00204.2005

Source DB:  PubMed          Journal:  Am J Physiol Renal Physiol        ISSN: 1522-1466


  126 in total

1.  Bigenic mouse models of focal segmental glomerulosclerosis involving pairwise interaction of CD2AP, Fyn, and synaptopodin.

Authors:  Tobias B Huber; Christopher Kwoh; Hui Wu; Katsuhiko Asanuma; Markus Gödel; Björn Hartleben; Ken J Blumer; Jeffrey H Miner; Peter Mundel; Andrey S Shaw
Journal:  J Clin Invest       Date:  2006-04-20       Impact factor: 14.808

2.  A susceptibility gene for kidney disease in an obese mouse model of type II diabetes maps to chromosome 8.

Authors:  Streamson Chua; Yifu Li; Shun Mei Liu; Ruijie Liu; Ka Tak Chan; Jeremiah Martino; Zongyu Zheng; Katalin Susztak; Vivette D D'Agati; Ali G Gharavi
Journal:  Kidney Int       Date:  2010-06-02       Impact factor: 10.612

3.  Increasing duration of type 1 diabetes perturbs the strength-structure relationship and increases brittleness of bone.

Authors:  Jeffry S Nyman; Jesse L Even; Chan-Hee Jo; Erik G Herbert; Matthew R Murry; Gael E Cockrell; Elizabeth C Wahl; R Clay Bunn; Charles K Lumpkin; John L Fowlkes; Kathryn M Thrailkill
Journal:  Bone       Date:  2010-12-23       Impact factor: 4.398

Review 4.  Understanding kidney disease: toward the integration of regulatory networks across species.

Authors:  Wenjun Ju; Frank C Brosius
Journal:  Semin Nephrol       Date:  2010-09       Impact factor: 5.299

5.  Investigation of the influence of nephropathy on monoclonal antibody disposition: a pharmacokinetic study in a mouse model of diabetic nephropathy.

Authors:  Frank A Engler; Bo Zheng; Joseph P Balthasar
Journal:  Pharm Res       Date:  2013-11-08       Impact factor: 4.200

Review 6.  Therapeutic potential of NADPH oxidase 1/4 inhibitors.

Authors:  G Teixeira; C Szyndralewiez; S Molango; S Carnesecchi; F Heitz; P Wiesel; J M Wood
Journal:  Br J Pharmacol       Date:  2016-07-14       Impact factor: 8.739

7.  Retinal angiogenesis in the Ins2(Akita) mouse model of diabetic retinopathy.

Authors:  Zongchao Han; Junjing Guo; Shannon M Conley; Muna I Naash
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-01-17       Impact factor: 4.799

8.  Markers of glycemic control in the mouse: comparisons of 6-h- and overnight-fasted blood glucoses to Hb A1c.

Authors:  Byoung Geun Han; Chuan-Ming Hao; Elena E Tchekneva; Ying-Ying Wang; Chieh Allen Lee; Benyamin Ebrahim; Raymond C Harris; Timothy S Kern; David H Wasserman; Matthew D Breyer; Zhonghua Qi
Journal:  Am J Physiol Endocrinol Metab       Date:  2008-07-29       Impact factor: 4.310

9.  Rosiglitazone reduces renal and plasma markers of oxidative injury and reverses urinary metabolite abnormalities in the amelioration of diabetic nephropathy.

Authors:  Hongyu Zhang; Jharna Saha; Jaeman Byun; MaryLee Schin; Matthew Lorenz; Robert T Kennedy; Matthias Kretzler; Eva L Feldman; Subramaniam Pennathur; Frank C Brosius
Journal:  Am J Physiol Renal Physiol       Date:  2008-07-30

Review 10.  Diabetes and cardiovascular autonomic dysfunction: application of animal models.

Authors:  Katia De Angelis; Maria Claudia Irigoyen; Mariana Morris
Journal:  Auton Neurosci       Date:  2008-12-02       Impact factor: 3.145

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.